Filter search criteria using below inputs
Click on magnifying glass icon to search
Company | Country | Symbol |
---|
Time | Volume | RPTX |
---|---|---|
09:32 ET | 293 | 3.45 |
09:50 ET | 200 | 3.41 |
10:06 ET | 100 | 3.385 |
10:14 ET | 200 | 3.4 |
10:19 ET | 400 | 3.4 |
10:35 ET | 493 | 3.38 |
10:46 ET | 166 | 3.35 |
10:48 ET | 100 | 3.375 |
10:53 ET | 100 | 3.375 |
11:04 ET | 100 | 3.35 |
11:06 ET | 100 | 3.345 |
11:08 ET | 999 | 3.3201 |
11:09 ET | 4115 | 3.36 |
11:15 ET | 100 | 3.365 |
11:22 ET | 650 | 3.36 |
11:42 ET | 100 | 3.36 |
11:49 ET | 100 | 3.36 |
11:54 ET | 200 | 3.38 |
11:56 ET | 100 | 3.39 |
12:12 ET | 2443 | 3.3899 |
12:21 ET | 100 | 3.375 |
12:23 ET | 923 | 3.4 |
12:30 ET | 1125 | 3.363 |
12:36 ET | 300 | 3.36 |
01:01 ET | 300 | 3.37 |
01:15 ET | 4854 | 3.35 |
01:39 ET | 500 | 3.37 |
02:02 ET | 260 | 3.37 |
02:20 ET | 100 | 3.38 |
02:27 ET | 100 | 3.38 |
02:42 ET | 2000 | 3.355 |
03:20 ET | 199 | 3.3416 |
03:30 ET | 300 | 3.345 |
03:45 ET | 614 | 3.34 |
03:50 ET | 950 | 3.335 |
03:52 ET | 200 | 3.35 |
03:56 ET | 100 | 3.3484 |
03:57 ET | 2307 | 3.33 |
03:59 ET | 8815 | 3.35 |
Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
---|---|---|---|
Repare Therapeutics Inc | 146.4M | -2.1x | --- |
Innate Pharma SA | 151.0M | -4.1x | --- |
Adaptimmune Therapeutics PLC | 178.2M | -2.1x | --- |
Champions Oncology Inc | 51.5M | -15.4x | --- |
Precision BioSciences Inc | 58.4M | -62.8x | --- |
Metagenomi Inc | 78.7M | -0.8x | --- |
Repare Therapeutics Inc. is a clinical-stage precision oncology company enabled by its proprietary synthetic lethality approach to the discovery and development of novel therapeutics. The Company utilizes its genome-wide, CRISPR-enabled SNIPRx platform to systematically discover and develop highly targeted cancer therapies focused on genomic instability, including DNA damage repair. Its pipeline includes lunresertib (RP-6306), a PKMYT1 inhibitor in Phase 1/2 clinical development; camonsertib (RP-3500), a potential Ataxia-Telangiectasia and Rad3-related protein kinase (ATR) inhibitor in Phase 1/2 clinical development; RP-1664, a Phase 1 PLK4 inhibitor; RP-3467, a preclinical polymerase theta adenosinetriphosphatase (ATPase) inhibitor program, and additional, undisclosed preclinical programs. RP-3500 is a potent and selective oral small molecule inhibitor of ATR in clinical development for the treatment of solid tumors with specific DNA damage repair-related genomic alterations.
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $146.4M |
---|---|
Revenue (TTM) | $68.7M |
Shares Outstanding | 42.4M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 0.71 |
EPS | $-1.63 |
Book Value | $5.03 |
P/E Ratio | -2.1x |
Price/Sales (TTM) | 2.1 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -139.46% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.